Application of PARP1 inhibitor in preparation of medicine for reversing drug resistance of tumor cells to amethopterin

A tumor cell, methotrexate technology, applied in antitumor drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as poor fidelity and abnormal chromosome structure

Active Publication Date: 2017-03-15
HARBIN MEDICAL UNIVERSITY
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the A-NHEJ repair process often produces large genomic deletions, microhomologies, and large insertions of DNA fragments of unknown origin, which is a less fidelity, more prone to genome rearrangement, and abnormal chromosome structure.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PARP1 inhibitor in preparation of medicine for reversing drug resistance of tumor cells to amethopterin
  • Application of PARP1 inhibitor in preparation of medicine for reversing drug resistance of tumor cells to amethopterin
  • Application of PARP1 inhibitor in preparation of medicine for reversing drug resistance of tumor cells to amethopterin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] 1. Cell culture

[0061] Human colon cancer cell line HT29 and HT29 MTX drug-resistant cells containing DMs (HT29 10 -4 mol / L MTX), cultured in DMEM high-glucose medium containing 15% fetal bovine serum, and corresponding concentrations of MTX were added to the culture medium of drug-resistant cell lines. All cells were in 5% CO 2 , Cultured in a 37°C cell culture incubator.

[0062] 2. Expression analysis of A-NHEJ pathway-related proteins

[0063] The total cell protein was extracted, and the expression changes of PARP1, LIG3 and XRCC1 in HT29 and HT29 MTX-resistant cells containing DMs were detected by Western Blot method.

[0064] a. Extraction of total cell protein

[0065] The cells were washed 3 times with pre-cooled PBS to remove the protein components attached to the cell surface. Place the cell culture flask on ice and aspirate the residual PBS. Add an appropriate amount of cell lysate (the volume ratio of protease inhibitor: phosphatase inhibitor: RIPAb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a PARP1 inhibitor in the preparation of a medicine for reversing drug resistance of tumor cells to amethopterin and belongs to the technical field of tumour biotherapy. It is found by the inventor through researches that as for malignant cells with MTX resistance and DHFR gene high-amplification, by specifically inhibiting the key protein RARP1 of A-NHEJ pathway, DHFR gene copy number can be reduce and DMs in cells can be decreased so as to reverse drug resistance of tumors and enhance efficiency of tumor therapy. Therefore, on the basis of the above researches, the invention brings forward the application of the PARP1 inhibitor in the preparation of a medicine for reversing the drug resistance of tumor cells to MTX by reducing DHFR gene copy number. The invention provides a new targeting therapeutic scheme for the MTX as the main therapeutic drug and for the biotherapy of malignant tumors which are easy to resist drugs and also provides a scientific basis for effectively fighting against MTX drug resistance. In addition, the invention is also of great positive significance for deeply understanding the nature of chemotherapy resistance and finding resistance target for individualized treatment.

Description

technical field [0001] The invention relates to a method for PARP1 inhibitors to reverse the drug resistance of tumor cells to MTX by reducing the copy number of DHFR gene in tumor cells, providing a scientific basis for revealing new therapeutic targets and more effectively combating MTX drug resistance, belonging to tumor biology The field of therapeutic technology. Background technique [0002] Methotrexate (Methotrexate, MTX) is an antifolate antineoplastic drug that can competitively bind to dihydrofolate reductase (Dihydrofolatereductase, DHFR) to inhibit nucleotide metabolism, thereby blocking DNA synthesis and specifically killing proliferating cells. However, in the process of tumor treatment, long-term continuous administration will cause tumor cells to acquire drug resistance, making the treatment effect poor. DHFR gene amplification and increased enzyme levels are important mechanisms leading to MTX resistance. Gene amplification refers to the phenomenon of a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K48/00A61K31/4184A61K31/519A61P35/00
CPCA61K31/4184A61K31/519A61K45/00A61K48/005
Inventor 孟祥宁侯丽青高巍关荣伟刘鹏冀国华马金法宋盈
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap